Mental Health

Important health screenings for patients taking antipsychotic medication are not being carried out in certain patient groups.

Cancer diagnosis may potentially cause a decrease in physical function and mental health.

Depression and anxiety strongly influences the success of cancer treatment.

The FDA has approved Vraylar, an atypical antipsychotic, for the treatment of schizophrenia and the acute treatment of mixed or manic episodes associated with bipolar I disorder.

I saw a sign today. It was in my psychiatrist's office, and it told me that May is Mental Health Awareness Month.

Interventions for bipolar patients can include group sessions, individual therapy, telephone, and e-mail to deliver adherence messages.

Patients diagnosed with bipolar disorder are at very high risk for medication nonadherence.

There is a potential correlation between aripiprazole use and increased risk for compulsive gambling and hypersexuality.

Researchers push for insurance to cover exercise programs for patients with mental illness.

Combining lamotrigine with quetiapine may improve depressive symptoms and clinical remission rates in patients with bipolar disorder.

How many of these off-label uses have you seen before?

While I was getting changed after a workout at the local YMCA, a familiar face got my attention.

The FDA has approved cariprazine (Vraylar) to treat schizophrenia and manic or mixed episodes associated with bipolar disorder.

Clinicians would like to have better information about treatment options for bipolar depression, but clinical trials of any length are scarce.

In the recent past, bipolar disorder has been classified as the most costly mental illness.

Patients with bipolar disorder who have lingering levels of symptoms and instable moods between episodes often relapse and require hospitalization.

Current medication regimens used in bipolar I disorder produce suboptimal patient outcomes more often than not.

Poor medication adherence increases the risk of relapse, hospitalization, and suicide in patients with bipolar disorder.

Longer duration of untreated illness (DUI) has been associated with poor clinical outcomes for many mood disorders, but not specifically bipolar disorder.

The FDA has extended its review of Richter and Allergan's atypical antipsychotic, cariprazine, for the treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder.

Lithium remains a treatment of choice for bipolar disorder, as it is very effective in stabilizing mood and reducing suicide risk. However, its use is associated with adverse renal and thyroid effects.

Favorable evidence supports the drug's utility in certain psychiatric and neurological disorders.

The search for better treatment approaches has led clinicians to use atypical antipsychotics to augment or replace conventional approaches.

The FDA today approved the first generic versions of aripiprazole to treat schizophrenia and bipolar disorder.

Many patients with depressive disorders self-treat with complementary and alternative medicine.